
    
      To evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (Taro
      Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals,
      U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.
    
  